Inovio launches Phase I/IIa trial for MERS infection in South Korea
US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea. (Source: Drug Development Technology)
Source: Drug Development Technology - September 18, 2017 Category: Pharmaceuticals Source Type: news
TG Therapeutics commences enrolment for Phase III multiple sclerosis trials
US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme of TG-1101 (ublituximab) to treat patients with relapsing multiple sclerosis (RMS). (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news
Phrixus to study P-188 NF in Phase II trial to treat DMD
US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news
Novo Nordisk ’s Tresiba minimises hypoglycaemia rate in diabetes trial
Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news
Pfizer and Astellas report positive Phase III data from prostate cancer trial
Pfizer and Astellas Pharma have reported positive results from a Phase III clinical trial (PROSPER) of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) to treat patients with non-metastatic (M0) castration-resistant prosta … (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2017 Category: Pharmaceuticals Source Type: news
Tulane University reports favourable results from new malaria trial
Tulane University in the US has reported positive results from a clinical trial of its new drug AQ-13, which is being developed for the treatment of malaria. (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2017 Category: Pharmaceuticals Source Type: news
M & As this week: inviCRO, Inotek Pharmaceuticals Corporation
inviCRO has completed the acquisition of UK-based translational research company Imanova. (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Synthetic Biologics, Bayer, HitGen
Synthetic Biologics has raised $12m through the private placement of 120,000 series A preferred shares priced at $100 a share. (Source: Drug Development Technology)
Source: Drug Development Technology - September 14, 2017 Category: Pharmaceuticals Source Type: news
OncoMed begins dosing GITRL-Fc in Phase Ia trial for solid tumours
US-based OncoMed Pharmaceuticals has begun dosing patients in a Phase Ia clinical trial of its therapeutic candidate GITRL-Fc (OMP-336B11) to treat patients suffering from solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news
GSK reports positive Phase III results of mepolizumab for COPD
GlaxoSmithKline (GSK) has reported positive results from two Phase III clinical trials of mepolizumab to treat patients with eosinophilic chronic obstructive pulmonary disease (COPD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news
Menarini and OBT conduct Phase I oncology trial of MEN1309
Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin ’s lymphoma (NH… (Source: Drug Development Technology)
Source: Drug Development Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news
Dyanamic Light Scattering - Common Terms Defined
There are a number of sources of information that give a mathematical description of the terms used in light scattering. However, these will not usually give assistance in understanding their practical application. (Source: Drug Development Technology)
Source: Drug Development Technology - September 13, 2017 Category: Pharmaceuticals Source Type: news
Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news
UCLA starts Phase I stem cell trial for cancers with NY-ESO-1 tumour marker
The University of California, Los Angeles (UCLA) has started a Phase I clinical trial to evaluate new genetically engineered blood-forming stem cells to treat cancers such as melanoma and sarcoma with a specific tumour marker called NY-ESO-1. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news
Zafgen studies ZGN-1061 in Phase II trial for type 2 diabetes
US-based biopharmaceutical firm Zafgen has started a Phase II clinical trial of its second-generation MetAP2 inhibitor ZGN-1061 to treat patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news
